<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01196871</url>
  </required_header>
  <id_info>
    <org_study_id>AT1001-013</org_study_id>
    <nct_id>NCT01196871</nct_id>
  </id_info>
  <brief_title>Drug-Drug Interaction Study Between AT1001 and Agalsidase in Subjects With Fabry Disease</brief_title>
  <official_title>An Open-label Phase 2A Study to Investigate Drug-Drug Interactions Between AT1001 and Agalsidase in Subjects With Fabry Disease.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amicus Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amicus Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effects of AT1001 on the safety of agalsidase,
      and the effects of agalsidase on the safety of AT1001.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma pharmacokinetics</measure>
    <time_frame>Over 24-hour period after dosing</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Fabry Disease</condition>
  <arm_group>
    <arm_group_label>Low dose A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lower dose of AT1001 with Fabrazyme.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Higher dose of AT1001 with Fabrazyme.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose AT1001 with Replagal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Higher dose of AT1001 with Replagal.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AT1001</intervention_name>
    <description>Capsules, single dose</description>
    <arm_group_label>Low dose A</arm_group_label>
    <arm_group_label>High dose A</arm_group_label>
    <arm_group_label>Low dose B</arm_group_label>
    <arm_group_label>High dose B</arm_group_label>
    <other_name>migalastat hydrochloride</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male diagnosed with Fabry disease and between 18 and 65 years of age, inclusive

          -  Body mass index between 18-35

          -  Subject initiated treatment with agalsidase at lease one month, having received at
             least two infusions, before the Screening Visit

          -  Subject's dose level, dosing regimen and form of agalsidase have been stable for at
             least one month before Screening Visit

          -  Subject has an estimated creatinine clearance greater than or equal to 50mL/min at
             Screening

          -  Subject agrees to use medically-accepted methods of contraception during the study and
             for 30 days after study completion

          -  Subject is willing and able to provide written informed consent

        Exclusion Criteria:

          -  Subject has had a documented transient ischemic attack, ischemic stroke, unstable
             angina, or myocardial infarction within the 3 months before Screening

          -  Subject has clinically significant unstable cardiac disease (e.g., cardiac disease
             requiring active management, such as symptomatic arrhythmia, unstable angina, or NYHA
             class III or IV congestive heart failure)

          -  Subject has a history of allergy or sensitivity to study drug (including excipients)
             or other iminosugars (e.g., miglustat, miglitol)

          -  Subject requires a concomitant medication prohibited by the protocol: Glyset®
             (miglitol), or Zavesca® (miglustat)

          -  Any investigational/experimental drug or device within 30 days of Screening, except
             for use of investigational ERT for Fabry Disease

          -  Subject has any intercurrent illness or condition that may preclude the subject from
             fulfilling the protocol requirements or suggests to the investigator that the
             potential subject may have an unacceptable risk by participating in this study
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor Clinical Research</last_name>
    <role>Study Director</role>
    <affiliation>Amicus Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Children's Hospital</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>O &amp; O Alpan LLC</name>
      <address>
        <city>Springfield</city>
        <state>Virginia</state>
        <zip>22152</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Linear Clinical Research</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital du Sacre-Coeur</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4J1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academisch Medisch Centrum (AMC)</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>France</country>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 7, 2010</study_first_submitted>
  <study_first_submitted_qc>September 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2010</study_first_posted>
  <disposition_first_submitted>July 18, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>July 18, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 22, 2013</disposition_first_posted>
  <last_update_submitted>December 19, 2013</last_update_submitted>
  <last_update_submitted_qc>December 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 27, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fabry disease</keyword>
  <keyword>drug drug interaction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fabry Disease</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>January 9, 2018</submitted>
    <returned>February 14, 2018</returned>
  </pending_results>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

